Lysophosphatidic Acid Biosynthesis Reprogramming And Biomarker Discovery In Hepatocellular Carcinoma

Lysophosphatidic Acid Biosynthesis Reprogramming And Biomarker Discovery In Hepatocellular Carcinoma

178 ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS 7.10. Combined Blockade Of Src Kinase And Epidermal Growth Factor ...

56KB Sizes 0 Downloads 57 Views

178

ASSOCIATION FOR ACADEMIC SURGERY AND SOCIETY OF UNIVERSITY SURGEONS—ABSTRACTS

7.10. Combined Blockade Of Src Kinase And Epidermal Growth Factor Receptor With Gemcitabine Overcomes STAT3-Mediated Resistance Of Inhibition Of Pancreatic Tumor Growth. E. H. Liu, N. S. Nagaraj, M. K. Washington, N. B. Merchant; Vanderbilt University Medical Center, Nashville, TN 7.11. Differential Regulation Of Tumor Suppressor PDCD4 Expression By Rapamycin. F. Adkins,1 W. Kim,1 A. Akcakanat,1 G. Singh,1 M. Hung,2 F. Meric-Bernstam1; 1 Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX; 2Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 7.12. Liposome-Encapsulated Curcumin Suppresses Neuroblastoma Growth Through Nuclear Factor-kB Pathway Inhibition. W. S. Orr,1,2 J. W. Denbo,1,2 C. Y. Ng,1 A. L. Myers,1,2 C. L. Morton,1 K. R. Saab,1 L. M. Pfeffer,3 A. M. Davidoff1,2; 1St Jude Children’s Research Hospital, Department of Surgery, Memphis, TN; 2University of Tennessee Health Science Center, Department of Surgery, Memphis, TN; 3University of Tennessee Health Science Center, Department of Pathology, Memphis, TN 7.13. Increased PIP3 Levels Reflect Aberrant PI3 Kinase Activity And Metastatic Capability In An Orthotopic Model of Colorectal Cancer. A. Rajput,1 M. Ongchin,2 G. Wan,1 E. Sharratt,3 B. Wilson4; 1Division of Surgical Oncology, Albuquerque, NM; 2Department of Surgery, Buffalo, NY; 3 Department of Pathology, Morgantown, WV; 4Department of Pathology, Albuquerque, NM 7.14. The Angiotensin II Type 2 Receptor Blocker, PD 123319, Inhibits Fatty Acid Synthase Production Through Activation Of AMP-Activated Protein Kinase In Pancreatic Cancer Cells. A. McGhee, Q. Gong, G. Chipitsyna, M. Sivarajah, C. J. Yeo, H. Arafat; Thomas Jefferson University, Philadelphia, PA

7.15. Raf Kinase Inhibitory Protein (RKIP) Mediates EtOHinduced Sensitization of Secretagogue Signaling in Pancreatic Acinar Cells. S. O. Kim, K. L. Ives, J. Park, X. Wang, C. D. Djukom, C. Chao, M. R. Hellmich; University of Texas Medical Branch, Galveston, TX

7.16. Integrin-Linked Kinase (ILK) Co-Localizes with PTEN in Regulating PI3K/Akt Activity in Neuroblastoma Cells. C. Taylor, J. Qiao, E. Josifi, D. H. Chung; Vanderbilt University Medical Center, Nashville, TN

7.19. Epigenetic Silencing of EzH2 By RNA Interference As A Potential Therapy For Pancreatic Adenocarcinoma. R. B. Batchu,1,2 A. M. Qazi,1,2,4 A. Y. Semaan,2,3 S. M. Seward,2,3 S. Chamala,1,2 V. B. Dhulipala,1,2 C. David,1 C. S. Bryant,3 S. Kumar,3 C. Steffes,1,2,4 P. Philip,1,4 D. Bouwman,1,4 D. W. Weaver1,2,4; 1Wayne State University, Detroit, MI; 2John D Dingell VA Medical Center, Detroit, MI; 3Wayne State University, Detroit, MI; 4Karmanos Cancer Institute, Detroit, MI 7.20. Silencing of CDC42 Inhibits Neuroblastoma Cell Proliferation and Transformation via Downregulation of TWIST and AKT2. S. Lee, J. Qiao, J. Zhang, D. H. Chung; Vanderbilt University Medical Center, Nashville, TN

ONCOLOGY 3: WOMEN’S HEALTH: BREAST & REPRODUCTIVE SYSTEM 8.1. Malignancies Associated With Germline And Somatic NF1 Gene Mutations. S. Patil1 R. Chamberlain1,2,3; 1 Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ; 2Saint Georges University School of Medicine, Grenada, Grenada; 3Department of Surgery, University of Medicine and Dentistry of New Jersey, Newark, NJ 8.2. Undocumented Status Does Not Decrease Survival in Medically Underserved Breast Cancer Patients. E. Castro-Echeverry, L. S. Kao, C. J. Wray; University of Texas Medical School At Houston, Houston, TX

8.3. Current Use of Perioperative Antibiotics Among Breast Cancer Patients. C. Dodgion,1 A. Karcz,3 W. Jiang,1 S. Lipsitz,1 C. Greenberg1,2; 1Center for Surgery and Public Health - Brigham and Women’s Hospital, Boston, MA; 2Center for Outcomes & Policy Research, Dana Farber Cancer Insititute, Boston, MA; 3Institute for Health Metrics, Burlington, MA 8.4. Differences In Approach To Breast Conservation Operations: Fellowship Trained Vs Nonfellowship Trained Breast Surgeons. S. L. Blair,1 V. Roma,2 V. Malcarne2; 1 University of California San Diego, Moores’ Cancer Center, La Jolla, CA; 2San Diego State University, Department of Psychology, San Diego, CA 8.5. Factors Affecting Survival Following First Locoregional Recurrence After Surgically Managed Breast Cancer. C. L. Crutcher A. B. Chagpar; University of Louisville, Louisville, KY

7.17. Exposure To Bile Acids Alters Intracellular Expression Of MnSOD In Barrett’s Esophagus. R. Farmer, Y. Li, X. Kang, N. Harper, R. C. Martin; University of Louisville Depatment of Surgery - Division of Surgical Oncology, Louisville, Ky

8.6. Outcomes After Tumescence Technique Vs. Electrocatuery Mastectomy. A. M. Abbott, B. T. Miller, T. M. Tuttle; University of Minnesota, Minneapolis, MN

7.18. Lysophosphatidic Acid Biosynthesis Reprogramming And Biomarker Discovery In Hepatocellular Carcinoma. S. Samuel, J. Wu, N. Skill, M. Maluccio; Indiana University, Indianapolis, IN

8.7. Impact Of a Free Access Multidisciplinary Program On Reducing Breast Cancer Disparities By Insurance Status. E. C. Feliberti, S. C. Azoury, R. C. Britt, J. N. Collins, R. R. Perry; Eastern Virginia Medical School, Norfolk, VA